An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects

This is an open-label, single-sequence, two-way drug interaction study to investigate the PK,
safety and tolerability of GSK3640254 and DTG when administered alone or in combination in
healthy subjects. Treatment of human immunodeficiency virus (HIV) infection frequently
involves combination therapy. Data from this study will contribute to dosing recommendations
when GSK3640254 and DTG are given in combination. The study will consist of a Screening
period and 3 sequential treatment periods. Subjects will be administered DTG 50 milligrams
(mg) once daily (QD) in Period 1 followed by GSK3640254 200 mg QD in Period 2. There will be
a washout period of 4 days between Periods 1 and 2. In Period 3, subjects will be
co-administered DTG 50 mg QD and GSK3640254 200 mg QD. The total duration of the study will
be approximately 55 days, including Screening.